A citation-based method for searching scientific literature

Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel, Coert J Zuurbier. Diabetologia 2018
Times Cited: 190



Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett, Shaun G Goodman, Ronald M Goldenberg, Mohammed Al-Omran, Richard E Gilbert, Deepak L Bhatt, Lawrence A Leiter, Peter Jüni, Bernard Zinman, Kim A Connelly. Circulation 2019
Times Cited: 152




List of shared articles



Times cited

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
12

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
50

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
5

SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh. Heart 2021
7

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
B Gaborit, P Ancel, A E Abdullah, F Maurice, I Abdesselam, A Calen, A Soghomonian, M Houssays, I Varlet, M Eisinger,[...]. Cardiovasc Diabetol 2021
3


An evaluation of canagliflozin for the treatment of type 2 diabetes: an update.
Taichi Minami, Akiko Kameda, Yasuo Terauchi. Expert Opin Pharmacother 2021
0

SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
Steffen Pabel, Nazha Hamdani, Mark Luedde, Samuel Sossalla. Curr Heart Fail Rep 2021
0

SGLT2 inhibitors in heart failure with reduced ejection fraction.
Uday Sankar Das, Aritra Paul, Suvro Banerjee. Egypt Heart J 2021
0


Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.
Claudia Penna, Ioanna Andreadou, Manuela Aragno, Christophe Beauloye, Luc Bertrand, Antigone Lazou, Ines Falcão-Pires, Robert Bell, Coert J Zuurbier, Pasquale Pagliaro,[...]. Br J Pharmacol 2020
28

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020
30


Diabetic cardiomyopathy.
A Lorenzo-Almorós, J M Cepeda-Rodrigo, Ó Lorenzo. Rev Clin Esp 2020
1